A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
This study aims to compare the efficacy and safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/PD1 (Pola-RCHP-X) versus RCHOP-X and Pola-RCHP in previously untreated patients with DLBCL.
Diffuse Large B Cell Lymphoma
DRUG: Polatuzumab vedotin|DRUG: Rituximab|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisone|DRUG: Orelabrutinib|DRUG: Venetoclax|DRUG: Chidamide|DRUG: Penpulimab|DRUG: Lenalidomide
Progression Free Survival at 24 months (PFS24) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma, At 24 months
Complete Response Rate (CRR) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma, End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 8 [Cycle length=21 days]|Overall Response Rate (ORR) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma, End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 8 [Cycle length=21 days]|Event Free Survival (EFS) Assessed by Investigator per Lugano Response Criteria for Malignant Lymphoma, up to approximately 48 months|Overall Survival (OS), up to approximately 48 months|Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), From enrollment to study completion, a maximum of 48 months
This study aims to compare the efficacy and safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/PD1 (Pola-RCHP-X) versus RCHOP-X and Pola-RCHP in previously untreated patients with DLBCL.